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Dissecting components of key transcriptional net-
works is essential for understanding complex devel-
opmental processes and phenotypes. Genetic studies
have highlighted the role of members of the Mef2 fam-
ily of transcription factors as essential regulators in
myogenesis from flies to man. To understand how
these transcription factors control diverse processes
in muscle development, we have combined chromatin
immunoprecipitation analysis with gene expression
profiling to obtain a temporal map of Mef2 activity dur-
ing Drosophila embryonic development. This global
approach revealed three temporal patterns of Mef2 en-
hancer binding, providing a glimpse of dynamic en-
hancer use within the context of a developing embryo.
Our results provide mechanistic insight into the regu-
lation of Mef2’s activity at the level of DNA binding and
suggest cooperativity with the bHLH protein Twist.
The number and diversity of new direct target genes
indicates a much broader role for Mef2, at all stages
of myogenesis, than previously anticipated.
Introduction
Embryogenesis requires the establishment of complex
spatiotemporal patterns of gene expression, which are
tightly orchestrated to ensure proper progression
through development. High-throughput in situ hybrid-
ization screens have dramatically increased our knowl-
edge of the number of genes expressed at a specific
time and cell type during development. Yet, information
on how these precise patterns are established, main-
tained, and dissipated remains very limited. Under-
standing the regulation of these complex patterns will
require dissecting the components of key transcrip-
tional networks, identifying the location of active cis-
regulatory modules (CRMs), and understanding the reg-
ulatory code within them.
Many key transcriptional regulators involved in mus-
cle development have been identified in a wide range
of species. Genetic studies highlighted the essential
role of the myocyte enhancing factor 2 (Mef2) and the
myogenic regulatory factor (MRF) families of transcrip-
tion factors. Nevertheless, due to the small number of
characterized muscle enhancers, our understanding of
the transcriptional combinatorial code required to regu-
late expression in different myoblast subpopulations is
*Correspondence: furlong@embl.devery limited. The temporal regulation of coordinated
gene expression, necessary for an ordered progression
through muscle development, has only been addressed
in a limited number of recent studies (Gaudet et al., 2004;
Penn et al., 2004).
Understanding Mef2 function during vertebrate devel-
opment is complicated by potential functional redun-
dancy between the four family members, which are ex-
pressed in overlapping patterns during embryogenesis.
The genome of Drosophila melanogaster contains only
one Mef2 gene, which, like in vertebrates, is expressed
in all muscle types (Nguyen et al., 1994). This provides
a unique opportunity to dissect the regulatory role of
myocyte enhancing factors in vivo. The DNA binding do-
main of Mef2 proteins is highly conserved, as is their rec-
ognition of a degenerate consensus (Black and Olson,
1998) and their essential function in muscle development
(Bour et al., 1995; Lin et al., 1997b; Naya et al., 2002;
Wang et al., 2003). This suggests that Mef2 regulation
of muscle genes inDrosophila is likely to be evolutionary
conserved. For many of the Mef2 target genes identified
to date, this is certainly the case (reviewed by Black and
Olson, 1998).
Previous studies aimed at identifying genes directly
regulated by Mef2 fall into two broad categories: com-
putational studies based on the prediction of Mef2 bind-
ing sites, or experimental identification of Mef2 bound
promoter regions.
Computational prediction of sites bound by Mef2 is
complicated by the degeneracy of its consensus bind-
ing site. Additional constraints, limiting the search space
to regions close to known muscle genes or assuming
clustering with additional motifs, for example, can re-
duce the number of false positive predictions. However,
this precludes the discovery of enhancer regions not
conforming to the formulated model. A recent study
in Drosophila (Junion et al., 2005) verified 62 out of 99
computational predictions of Mef2 bound enhancers
by using chromatin immunoprecipitations and provided
the largest number of Mef2-regulated modules to date.
Although this prediction-based approach identified
new targets with high accuracy, due to the restrictions
used in the model only a limited fraction of the genome
was sampled and only known mesodermal genes could
be identified as targets.
Two studies applied an experimental approach, chro-
matin immunoprecipitation of Mef2 from mammalian
C2C12 cells, to identify promoters bound by Mef2A
(Paris et al., 2004) or Mef2C (Blais et al., 2005). While
more than 20 target genes were identified in each study,
the analysis of enriched sequences with promoter or
CpG island arrays could only detect Mef2 binding close
to transcriptional start sites, a very limited fraction of the
genome. Additionally, though C2C12 cells are a well-
established model by which to study differentiation, the
extent to which this system mimics muscle development
in vivo remains unclear.
Therefore, the studies conducted to date cannot pro-
vide an unbiased map of Mef2 enhancer binding during
development. The extent to which this transcription
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798factor regulates the myogenic program remains unclear,
as an accurate estimate of the number of enhancers
bound in vivo and of the regulated target genes is not
available. Moreover, the dynamics of Mef2 activity dur-
ing development have not been addressed to date.
We have used an unbiased approach to identify Mef2
bound enhancers and Mef2 direct target genes during
multiple consecutive stages of the developing Drosoph-
ila embryo. Complementary genomic approaches were
integrated to systematically understand the function of
this important transcription factor: (1) chromatin immu-
noprecipitation followed by microarray analysis (ChIP-
on-chip) with genomic tiling arrays was used to map
the position of Mef2 bound enhancers; (2) gene expres-
sion profiling of Mef2 mutant embryos during a time
course of development revealed genes requiring Mef2
for their correct expression.
The combination of ChIP-on-chip (distinguishing be-
tween direct and indirect regulation) and gene expres-
sion profiling of a loss-of-function mutant identified
more than 200 direct target genes, many of which are
differentially regulated in Mef2 mutants. Analyzing mul-
tiple time points of development identified three tempo-
ral profiles of enhancer occupancy, revealing regulation
of Mef2’s activity at the level of DNA binding. The diverse
functions of Mef2 direct target genes highlight a much
broader role for Mef2 in myogenesis than previously an-
ticipated and place Mef2 at the center of the myogenic
transcriptional hierarchy.
Results and Discussion
Enhancer Occupancy during Embryonic
Development
To identify enhancer regions bound by Mef2 in vivo,
chromatin immunoprecipitation followed by microarray
analysis (ChIP-on-chip) was performed at five consecu-
tive time points of embryogenesis spanning key stages
of muscle development (Figure 1A; Table S1; see the
Supplemental Data available with this article online).
To systematically identify Mef2 bound genomic regions
in an unbiased manner, we constructed aDrosophila ge-
nomic tiling array, taking advantage of genomic clones
generated by the Berkeley Drosophila Genome Project
(BDGP) to sequence the Drosophila genome (Adams
et al., 2000). The array consists of overlapping 3 kb frag-
ments tiling acrossw50% of the Drosophila genome.
For each developmental time period assayed, four in-
dependent embryo collections, chromatin preparations,
and chromatin immunoprecipitations were performed
(Figure 1B). To avoid false positives due to unspecific
binding of a single antibody, we performed the assays
with two different polyclonal antisera raised against
Mef2. Only genomic regions that were significantly en-
riched by both anti-Mef2 antibodies, but not in mock ex-
periments, were considered. This method is likely to be
very stringent and therefore provides a high confidence
that the enriched regions are specifically bound by Mef2.
These experiments identified 1015 significantly en-
riched Mef2 bound fragments, with less than 1% esti-
mated false positives. Due to the overlapping nature of
the array, this represents 670 nonoverlapping genomic
regions bound by Mef2 at one or more developmental
time points. To assess the quality of this data set, we de-termined if regions previously reported to be bound by
Mef2 were recovered. Eight of the previously character-
ized Mef2 direct target genes are covered by our arrays.
We identified Mef2 binding in the proximity of all eight
genes assayed (Figures 1C and 1D; Figure S1): Actin
57B (Kelly et al., 2002), Muscle LIM protein at 84B and
Muscle LIMprotein at 60A (Stronach et al., 1999), b-tubu-
lin60D (Damm et al., 1998), Tropomyosin I (Lin and Storti,
1997), inflated (Ranganayakulu et al., 1995), mir-1 (Sokol
and Ambros, 2005), andMef2 itself (Cripps et al., 2004). In
many cases, our study not only identified the previously
reported Mef2 bound enhancer, but also identified ad-
ditional ones (Figures 1C and 1D, asterisk; Figure S1A).
Five genes are known to be genetically downstream of
Mef2, though the mechanism of regulation remains un-
clear: Myosin heavy chain (Bour et al., 1995; Lilly et al.,
1995), meso18E (Taylor, 2000), muscleblind (Artero
et al., 1998), nautilus (Lin et al., 1997a), and Chorion fac-
tor 2 (Bagni et al., 2002). Our results show Mef2 binding
to genomic regions close to four of these genes (Mhc,
mbl, nau, and meso18E) and to a genomic region further
50 of CF2 (Figure S1). This indicates that these genes are
directly regulated by Mef2 and identifies the location of
at least one of their enhancer regions. In summary, the
successful identification of Mef2 binding in the vicinity
of all known and suspected target genes suggests a
high accuracy of our approach. In addition to the 8
known enhancers, we have identified over 650 new
Mef2 bound regions.
A High-Resolution Developmental Time Course
of Mef2-Dependent Gene Expression
As a complementary approach to assess the molecular
function of Mef2, we determined which genes depend
on Mef2 activity for their correct expression during
embryonic development. The gene expression profile
of wild-type embryos was compared to that of stage-
matched Mef2 mutant embryos throughout a develop-
mental time series. Pure populations of Mef2 homo-
zygous mutant embryos were isolated as described
previously (Furlong et al., 2001a, 2001b). For each devel-
opmental time point assayed, four independent repli-
cates were analyzed on microarrays containing at least
one probe for every predicted gene in the genome.
We examined the expression profiles of Mef2 mutant
embryos at 11 consecutive 1 hr time points of embryo-
genesis, spanning from 5 to 16 hr of development
(stages 9–16; Table S1). An additional time point was
added at 18–19 hr, stage 17, to identify genes that are
expressed in differentiated muscle. This allowed us to
generate a high-resolution map ofMef2-dependent tem-
poral changes in gene expression, spanning the stages
of mesoderm subdivision, myoblast specification, myo-
blast fusion, and the initiation of terminal muscle differ-
entiation (Figure 1A).
This study identified 700 genes with significant
changes in gene expression in Mef2 mutant embryos
at 2 or more consecutive time points (Figure S2; Table
S2). The eight known Mef2 protein-coding target genes
are among them, with Act57B, Mlp84B, Mlp60A, and
TmI showing a greater than 4-fold decrease in expres-
sion at multiple stages of development. The differentially
expressed genes are significantly enriched in genes ex-
pressed in muscle (p < 0.005), indicating that many of the
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(A) Temporal analysis of Mef2 function during myogenesis: Mef2 enhancer binding was assayed at five consecutive 2 hr time points (orange
bars), covering the stages of myoblast specification, fusion, and the initiation of terminal differentiation. This information was complemented
by expression profiling of Mef2 mutant embryos at 12 one hr time points (blue bars).
(B) Experimental design of the ChIP-on-chip experiment: for each developmental time point, the four replicate samples were divided into two
groups, which were probed with a-Mef2 antisera (ChIP) raised in two different animals and with respective preimmune sera (mock). All eight
precipitations were hybridized against a genomic reference DNA sample on genomic tiling arrays. SAM analysis was used to identify regions
specifically enriched in ChIP, but not mock, pull-downs.
(C and D) Schematic overviews of two known Mef2 enhancers: the gene loci for act57B and b3Tub60D are located on the sense strand, indicated
at the top of the panels (orange). Genomic fragments on the tiling arrays are indicated as stacks of five horizontal bars in their corresponding
genomic position. Each single bar represents the results from one ChIP-on-chip time point, with the earliest (2–4 hr) positioned at the top
and the latest (10–12 hr) at the bottom (blue arrow). Significant binding of Mef2, indicated in red, is found for the previously characterized
Mef2 binding site (arrowhead) as well as for a previously unknown Mef2 bound region (asterisk).misregulated genes are expressed in the same cells as
Mef2.
The function of a substantial number of the differen-
tially expressed genes is unknown. This study indicates
that they are genetically downstream of Mef2 as either
direct or indirect targets, and provides a useful resource
to identify genes likely to be involved in muscle develop-
ment. The combination of our ChIP-on-chip results with
this expression profiling data allowed us to determine
which genes are directly regulated by Mef2.
Identifying Mef2 Direct Target Genes: Integrating
ChIP-on-Chip with Gene Expression Data
Genomic tiling arrays provide an unbiased method to
identify new regulatory regions independent of their dis-tance to the gene. While this offers a great advantage
over promoter arrays, it raises a new challenge for
ChIP-on-chip studies: how to accurately match tran-
scription factor bound regions to their correct target
genes. Metazoan enhancers have been identified at
large distances from their target genes, including within
introns of neighboring loci. Assuming that the enhancer
is regulating the closest proximal gene will, especially in
gene-dense regions, often cause the wrong target gene
to be selected.
We have used different sources of metadata to sys-
tematically link ChIP-enriched regions to their target
genes (Figure S3). The genes in the vicinity of each
Mef2 bound region received a cumulative score based
on: (1) the distance between a gene and a Mef2 bound
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bryos, and (3) supporting information, for example about
the gene’s expression patterns (BDGP in situ database,
Flybase, literature). Genes were not assigned based on
proximity alone. Using this approach, we identified 211
Mef2 direct target genes with high confidence (Table
S3), including all known targets covered by the tiling array.
To estimate the accuracy of our automated gene
assignment, we used a collection of characterized en-
hancers from single gene studies (Bergman et al.,
2005; Gallo et al., 2006). A total of 33 of the Mef2 bound
regions assigned to target genes with a high confidence
score overlap with a previously identified gene’s en-
hancer. In 28 cases (84.8%), the regulated locus was
correctly identified (Table S4), illustrating the accuracy
of our gene assignment strategy. The remaining five se-
quences map to the Enhancer of split region and were
assigned to a different member of this gene cluster. A to-
tal of 29 additional Mef2 bound regions overlapped with
known enhancer regions. The 12 regulated target genes
were not assigned by using our automated approach,
as no additional supporting evidence was available.
Combining the automatic assignments with information
about known regulatory relationships yielded 234
unique genes directly regulated by Mef2.
Rather than potentially making an incorrect gene
assignment, we did not assign the remaining 574 Mef2
bound fragments to genes, although they are equally sig-
nificantly enriched with a stringent statistical cutoff. The
vast majority (87.3%) of unassigned Mef2 bound frag-
ments were in an intron or within 5 kb of one or more
genes (distance score > 0.89); therefore, they likely con-
tain regulatory modules. To enable other researchers
to make their own gene assignments, we have created
a searchable web site (http://furlonglab.embl.de/data/),
displaying all Mef2 bound regions in their genomic con-
text together with the results from our expression profil-
ing experiments.
Mef2 Bound Regions Can Function as Muscle
Enhancers In Vivo
Of the 1015 Mef2 bound regions, 62 were previously
identified as active enhancers (Tables S4 and S5). The
vast majority of these regulatory regions were not
known to bind to Mef2, but they have been shown to
bind to a number of other transcription factors in vitro,
revealing interesting insights into combinatorial gene
regulation with Mef2. For example, we identified Mef2
binding to an Antp bound enhancer region of the apter-
ous and teashirt genes. Many of these regions were
shown to function as muscle enhancers in vivo, provid-
ing additional evidence that our identified Mef2 bound
regions are active enhancers. To test if additional Mef2
bound regions can function as enhancers in vivo, we se-
lected five regions with representative levels of enrich-
ment in the ChIP-on-chip experiments that were as-
signed to target genes with known expression. This
allowed us to evaluate their ability to drive reporter
gene expression in a pattern similar to that of the target
gene. Using conservation in different Drosophila spe-
cies as a guide, regions between 0.4 and 2.5 kb within
the bound fragments were assayed.
All five Mef2 bound regions tested were able to drive
GFP expression in Mef2-expressing cells. The enhancerregion of pnt (Figure 2A00) initiates expression of GFP
early in the mesoderm, at stages 9–10. This mirrors the
expression of the pnt transcripts in wild-type embryos.
Since the GFP protein has a long half-life in Drosophila
embryos, it can subsequently be detected in differenti-
ating myoblasts. The enhancer regions of CG14687
(Figure 2B00) and CG5080 (Figure 2C00) initiate GFP ex-
pression slightly later. The enriched region upstream
of CG14687 is sufficient to direct expression of GFP ini-
tially in the visceral muscle (stage 11) and later in the so-
matic muscle (stage 12), closely resembling the spatial
and temporal expression pattern of the gene itself.
Myosin light chain 2 (Mlc2) is a target of Mef2 proteins
in vertebrates (Chambers et al., 1994; Navankasattusas
et al., 1992). Our data show that this regulation is con-
served in flies. A Mef2 bound region 50 of the Mlc2 locus
reproduces the gene’s expression, driving GFP expres-
sion in differentiating somatic muscle cells from stage
13 onward (Figure 2D00). Finally, the endogenous expres-
sion of CG9416 initiates in the longitudinal visceral mus-
cle precursors at stage 10 (Figure 2E0) and in the somatic
muscle at stage 13. A 372 bp enhancer region is sufficient
to direct GFP expression in both tissues, reproducing the
full expression pattern of CG9416 (Figure 2E00).
In summary, all five Mef2 bound genomic regions are
sufficient to direct reporter gene expression resembling
the temporal and spatial patterns of the respective pre-
dicted target gene. These results indicate that our ChIP-
on-chip approach was very successful in identifying
new muscle enhancers in vivo, and that our assignment
of target genes to Mef2 bound regions is accurate.
Mef2 Is Able to Direct Ectopic Expression of Novel
Target Genes in the Ectoderm
Many of the identified direct target genes are misex-
pressed inMef2mutant embryos, showing a requirement
for Mef2 for their normal expression (see Supplemental
Results). To determine if Mef2 is sufficient to regulate
its target genes in nonmuscle cells,Mef2was ectopically
expressed in the ectoderm by using the UAS/Gal4 sys-
tem. As putative cofactors are likely to be absent, this
assay is a very stringent test of a regulatory relationship.
Remarkably, Mef2 could induce ectopic expression of 5
of the 13 genes tested in nonmuscle cells. Overexpres-
sion of Mef2 in engrailed stripes in the ectoderm is suffi-
cient to cause ectopic expression of Him, CG9416, and
CG30080 (arrows, Figures 3A–3F). Overexpression of
Mef2 with lmd, a transcription factor known to regulate
Mef2 (Duan et al., 2001), is sufficient to drive ectopic ex-
pression ofCG5080anddelilah in the ectoderm (Figure 3;
arrows in [G]–[J]). Ectopic expression of either transcrip-
tion factor alone could not induce expression of these
genes, suggesting that Mef2 and Lmd cooperatively
regulate their expression and are sufficient to do so in
nonmuscle cells. These results, in combination with the
expression profiling data, confirm that Mef2 is essential
and sufficient for the expression of a large percentage
of its target genes.
Mef2 Binds to Enhancers in Three Temporal Patterns
during Development
While Mef2 is found in all muscle cells from gastrulation
to the end of embryogenesis, its known target genes
show temporally and spatially different expression
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(A–E) Schematic diagrams indicating the gene locus (orange), the genomic fragments on the tiling array (gray bars), the Mef2 bound fragments
(red bars), and the enhancer region tested (arrowed line). The five gray or red bars in each stack represent the results for each developmental time
point.
(A0–E0) In situ hybridization of transcripts in wild-type embryos.
(A00–E00) a-GFP immunohistochemistry of transgenic enhancer-GFP lines for the regions indicated in (A)–(E), respectively. Specific muscle stain-
ing reproducing the wild-type expression of the assigned target gene is observed in all enhancer lines tested, indicating that these Mef2 bound
regions are sufficient to function as muscle enhancers in vivo. For all embryos, anterior is to the left and dorsal is to the top.patterns. For example, Act57B and b3-tub60D RNA are
not transcribed untilwstage 11, while Mhc and Mlp84B
RNAs are not detectable until stages 13–14. Moreover,
while Mef2 is expressed in the entire myogenic lineage,
some of its known targets are expressed in smaller
subsets of cells.
Clearly, there must be additional ways to control
Mef2’s regulatory activity. To determine if regulation oc-
curs at the level of DNA binding, we used the temporal
information from the ChIP time course to investigate if
there are distinct patterns of Mef2 enhancer occupancy.
K-means clustering analysis was used to subdivide the
1015 enriched genomic regions according to their tem-
poral profile of Mef2 binding. Three major groups of tem-
porally bound enhancers were identified.
Binding to the first group of enhancers was initially
detected at 4–6 hr of development, after which Mef2
remained bound through the three subsequent develop-
mental time points assayed (Figure 4A, blue line, contin-
uous cluster). This group, representing almost half of the
enriched fragments, suggests that these enhancers re-
main occupied by Mef2 throughout development. This
temporal binding pattern of Mef2 matches its broad ex-
pression during all stages of muscle development.The second group, representing 21% of the en-
hancers, was bound by Mef2 at 4–6 hr of development,
but it was not bound at later developmental time points
(Figure 4A, green line, early cluster). As Mef2 continues
to be expressed, and is capable of binding to other en-
hancers, the transient occupancy of the early enhancers
demonstrates that Mef2’s ability to bind to DNA is tightly
regulated.
The third group, containing 32% of the enhancers, is
only bound by Mef2 late in development, with maximal
binding at the last time point assayed (Figure 4A, red
line, late cluster). This group contains enhancers for
many genes involved in late aspects of muscle differen-
tiation, e.g., Mhc, Mlc1, Mlc2, TmI, TmII, act57B, b3-
tub60D,Mlp60A,Mlp84b,Mp20,mbl, andwupA. Although
Mef2 protein is present at high levels early in develop-
ment, it does not occupy these enhancers until much
later, demonstrating additional specificity in the regula-
tion of Mef2 binding.
We investigated if the temporal binding of Mef2 to a
target gene’s enhancer coincides with the onset of that
gene’s expression. Remarkably, the first time point
when Mef2 binds to an enhancer is significantly corre-
lated with the onset of that gene’s expression during
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While this trend holds for all time points assayed, the cor-
relation is particularly strong for late bound enhancers
(>10 hr), mirroring the coordinated expression of late
muscle differentiation genes. Although additional levels
of ‘‘post binding’’ regulation cannot be excluded, these
results demonstrate that Mef2’s DNA binding is tightly
regulated and is a trigger for target gene expression.
To our knowledge, our results provide the first evi-
dence that, while Mef2 is broadly expressed during
muscle development, its ability to bind to DNA is tempo-
rally regulated depending on the context of the en-
hancer. This finding is intriguingly similar to what has
been shown for MyoD in fibroblasts (Bergstrom et al.,
2002) and Pha-4 inC. elegans (Gaudet et al., 2004). While
both transcription factors have broad temporal expres-
sion, they regulate temporally restricted enhancers. This
highlights a potentially general mechanism for encoding
spatiotemporal specificity within the context of a regula-
tory region.
The Presence of Regulatory Motifs Correlates
with Temporal Mef2 Binding
To explain the three temporal patterns of Mef2 binding,
we searched for regulatory motifs within each group of
Figure 3. Ectopic Mef2 Expression Can Induce Misexpression of
Several Target Genes
(A–J) (A, C, E, G, and I) In situ hybridization of wild-type embryos with
probes specific for (A) Him, (C) CG9416, (E) CG30080, (G) CG5080,
and (I) dei, detecting specific expression in the visceral and somatic
muscle. No specific staining was observed in the ectoderm (arrows).
An engrailed-Gal4 driver line was used to ectopically express (B, D,
and F) UAS-Mef2-HA or both (H and J) UAS-Mef2-HA and UAS-
lmd in ectodermal stripes. The expression of all five genes can be in-
duced in the ectoderm at stages 11–13 (arrows), either by (B, D, and
F) ectopic Mef2 alone or (H and J) in combination with ectopic Lmd.enhancers. We first determined if the number of Mef2
sites was equally distributed between the three tempo-
ral groups of Mef2 bound enhancers. Interestingly, en-
hancers in the continuously bound and the late bound
groups were significantly enriched in single and multiple
Mef2 sites per fragment (Figure 4B). This significant en-
richment of Mef2 sites is conserved in the ortologous se-
quences of the related species, Drosophila pseudoobs-
cura. In contrast, the early cluster of transiently bound
enhancers contains a similar number of Mef2 sites as
the rest of the genome.
The bHLH transcription factor Twist is essential for all
aspects of early mesoderm development in Drosophila.
Twist has a transient expression pattern, with peak ex-
pression at stage 11 (w6–7 hr) mirroring the peak bind-
ing of Mef2 to the early enhancers (Figure 4A). In vitro
studies have shown cooperative regulation between
vertebrate Mef2 proteins and bHLH transcription factors
via direct protein-protein intereactions (e.g., MyoD, Mol-
kentin et al., 1995, and Hand, Morin et al., 2005). Given
the temporal expression of Twist protein and the ability
of vertebrate Mef2 proteins to bind to bHLH proteins,
cooperative binding of Mef2 and Twist is an attractive
model to explain the transient Mef2 binding to the early
group of enhancers.
Two lines of evidence indicate that this hypothesis is
correct. First, Twist sites are significantly enriched in
the early bound enhancers (Figure 4C; p < 1024), and
not in the continuous and late bound enhancers. This
significant enrichment of Twist sites is conserved in
the ortologous sequences of D. pseudoobscura. Sec-
ond, Twist and Mef2 cobind to the early enhancers at
the same stage of development. We have performed
ChIP-on-chip studies of Twist at 4–6 hr of development
(manuscript in preparation). Comparing the results of
both studies showed in vivo binding of Twist to a large
percentage of the early enhancers, demonstrating that
Mef2 and Twist can cooccupy the early enhancers.
Figure 4D shows five examples of Mef2 bound early en-
hancers cobound by Twist at 4–6 hr of development.
While bHLH proteins have a central role in muscle de-
velopment in all species examined to date, the predom-
inant roles of individual family members have diverged.
In vertebrates, MyoD family members play a central role
in activating muscle gene expression, while Twist re-
presses myogenesis. In Drosophila, the only MyoD fam-
ily member, nau, is not essential for general muscle
development (Balagopalan et al., 2001). It has been
speculated that Twist is the central bHLH regulator of
Drosophila muscle development, as it is sufficient to ac-
tivate the myogenic program upon ectopic expression in
the ectoderm (Baylies and Bate, 1996). Our results pro-
vide further evidence for the evolutionary similar roles
of Twist in flies and vertebrate MRFs; Drosophila Twist
and Mef2 proteins may cooperatively regulate muscle
gene expression in a similar manner to MyoD and Mef2
proteins in vertebrates.
Examination of Mef2 Target Genes Reveals New
Insights into the Role of Mef2 inMuscle Development
Mef2 Coordinates Multiple Processes of Terminal
Muscle Differentiation
Embryos with loss-of-function mutations in Drosophila
Mef2 show a block of myoblast fusion and lack
A Developmental Time Course of Mef2 Activity
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Regions
(A) K-means nearest neighbor clustering identified three major tem-
poral patterns of Mef2 binding to 1004 enriched regions. Each line in
the graph represents the median enrichment for all fragments within
that group at a given time point. The early bound cluster is in green,
the continuously bound cluster is in blue, and the late bound cluster
is in red.
(B) Mef2 binding sites are overrepresented in the enriched regions:
using a position weight matrix (PWM) for Mef2, a significant enrich-
ment of one or more predicted binding sites was found in the contin-
uously bound (blue) and late bound (red) fragments (***p < 1028). The
y axis shows fold enrichment of the number of Mef2 sites in the en-
riched fragments, compared to the rest of the fragments on the array
(background).
(C) Twist binding sites are enriched in the early bound cluster: using
a PWM to predict Twist binding sites, a significant enrichment of one
or more sites per fragment was found only in the early bound cluster
(green) (*p < 0.05, **p < 1023, ***p < 1024).expression of a number of contractile muscle proteins
(Bour et al., 1995; Lilly et al., 1995). We have identified
a number of Mef2 target genes involved in both pro-
cesses; e.g., blow and lmd, two genes essential for myo-
blast fusion, as well as numerous cytoskeletal proteins
(Table S7).
In addition to these severe phenotypes, defects in
neuromuscular junction (NMJ) formation and muscle at-
tachments have been observed inMef2mutant embryos
(Prokop et al., 1996; Ranganayakulu et al., 1995), the
molecular basis of which is not understood. We find a
significant enrichment of Mef2 target genes involved in
both processes (Figure 5A, p < 0.01; Table S8), providing
a molecular understanding of the observed phenotypes.
Our results also indicate that Mef2 is required for mus-
cle function in differentiated myofibers. We identified
a number of Mef2 target genes involved in muscle en-
ergy production or storage: Pfrx, GluRIIA, GlyP, Gpdh,
Glycogenin, Pgi, and Pgk. This role may be further
strengthened by the direct regulation of Ptx1, a tran-
scription factor thought to regulate muscle physiology
(Vorbruggen et al., 1997).
An Early Role for Mef2 in the Regulation of Muscle
Identity Genes
Drosophila body wall muscles are formed from progeni-
tor cells that are selected through the action of Ras sig-
naling and Notch-Delta lateral inhibition (reviewed by
Furlong, 2004). Our data show in vivo binding of Mef2
to enhancer regions of a striking number of genes that
are essential for this process (Figure 6; red border), in ad-
dition to expression changes for some genes inMef2mu-
tant embryos (Figure 6; blue or yellow). This includes
components of the Notch-Delta pathway (Delta, mam,
bib, E(spl) complex, and Neur), which is essential for
specification of the somatic muscle and heart. As our ex-
periments were analyzed with tiling arrays covering 50%
of the genome, Mef2 likely regulates even more genes in-
volved in these signaling pathways, which we could not
identify. This is in agreement with Junion et al. (2005),
who identified sfl, spen, and argos as Mef2 targets.
Once specified, founder cells express a characteristic
set of transcription factors called identity genes. We
identified in vivo binding of Mef2 to enhancer regions
of eight of the ten known muscle identity genes (Figure 6,
green box; Figure S4). Importantly, the temporal binding
of Mef2 correlates with the initiation of identity gene ex-
pression in founder cells (stages 9–11; time points 4–6
and 6–8 hr). Mef2 also binds to enhancer regions of
a number of genes previously reported to be enriched
in founder cells, suggesting that Mef2 acts in concert
with the identity genes to regulate the transcriptional
program within these myoblasts (Ubx, htl, CG14207,
CG9520, CG17492, CG8417, Artero et al., 2003, and
krT95D in the VO5 muscle, Hartmann and Jackle, 1997).
Genetic studies looking at the interplay between mo-
tor neuron and muscle development observed a consis-
tent reduction in the number of somatic muscles in Mef2
(D) Twist cobinds to Mef2-early bound enhancers: chromatin immu-
noprecipitation was performed with an anti-Twist antibody at 4–6 hr
of development and was assayed by real-time PCR. Examples of five
sequences from the early Mef2-enriched cluster are shown to be
cobound by Twist (n = 2). Cooperative binding of Twist and Mef2
is likely regulating the transient binding of Mef2 to these enhancers.
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Genes Involved in Muscle Attachment
Depicted are a myotube on the left, a tendon
cell on the right, and the extracellular matrix
(ECM) in between. Gene products are repre-
sented in the expressing cell or in the ECM.
The color of the border of each gene repre-
sents the results from the ChIP-on-chip ex-
periment: genes with a thick, red border are
bound by Mef2, genes with a thin, black,
dashed border are not covered by the tiling
array, and a thick, gray border indicates cov-
erage on the array, but the loci are not bound
by Mef2. Blue and yellow represent the results
from expression profiling of Mef2 mutant em-
bryos, indicating reduced or increased ex-
pression, respectively. No gene expression
information for vn is available.mutants (Landgraf et al., 1999; Prokop et al., 1996). At
that time, it was not clear if the loss of muscles was
a secondary defect due to a general failure of the muscle
Figure 6. A New Role for Mef2: Regulation of Muscle Identity
A schematic overview of genes involved in somatic muscle specifi-
cation: The EGF-, FGF-, and Notch-Delta signaling pathways con-
verge to specify progenitor cells, which give rise to somatic muscle
founder cells. Founder cells express specific transcription factors or
identity genes. The colors used represent the results from ChIP-on-
chip (border) and expression profiling experiments (fill). The loci of
genes with a thick, red border were bound by Mef2, the loci of genes
with a thick, gray border were not bound by Mef2, and the loci of
genes with a thin, black, dashed border are not covered by the tiling
array. Blue and yellow represent the results from expression profil-
ing of Mef2 mutant embryos, indicating reduced or increased ex-
pression, respectively. Individual components of the Ras/MAPK
pathway (central square box) have been omitted for clarity.to differentiate, and the molecular mechanism was not
explored. Our results indicate that Mef2 directly regu-
lates founder cell identity gene expression. We suggest
that Mef2 provides an extra layer of regulation to buffer
this key step in muscle development from stochastic
fluctuations in the levels of key regulators. When this
regulation is absent in Mef2 mutant embryos, founder
cells are not specified or maintained in a robust manner,
leading to the observed low penetrance loss-of-muscles
phenotype.
Mef2 Is a Key Regulator of the Transcriptional
Circuitry Required for Muscle Development
Traditionally, Mef2 is placed toward the bottom of the
myogenic transcriptional hierarchy, due to its well-char-
acterized role as a regulator of muscle effector proteins.
Because of this, we were very surprised to find that Mef2
regulates a large number of transcription factors, many
of which are involved in early aspects of myogenesis
(Supplemental Results; Table S9). For example, Mef2
regulates transcription factors essential for visceral
muscle development (bap, slp1, HLH54F) and cardio-
blast specification (nmr2, Zfh1, ush). These results impli-
cate a role for Mef2 in the subdivision of the dorsal meso-
derm and place Mef2 at the center of the transcriptional
program required for Drosophila muscle development.
Vertebrate Mef2 proteins regulate the expression of
the transcription factors MyoD and cJun (Han and
Prywes, 1995; Wong et al., 1994). We find direct regula-
tion of the ortologs of these genes (nau, jra) byDrosoph-
ila Mef2, indicating that Mef2 is part of an evolutionary
conserved genetic program. This suggests that many
of the additional transcriptional connections that we
have identified in Drosophila may also be conserved.
A New View of Mef2 as a Global Regulator of Muscle
Gene Expression in Drosophila
One of the most surprising findings of this study was the
large number of enhancer regions that are bound by
Mef2. Previous studies searching for Mef2 targets fo-
cused on a limited part of the genome. To our knowledge,
the present study is the most comprehensive and unbi-
ased report to date and thereby provides a unique op-
portunity to get a more accurate view of the total number
of Mef2-regulated enhancers and genes. Using a tiling
array coveringw50% of the genome, we have identified
at least 670 unique Mef2 bound genomic regions. A total
of 600 of these enhancer regions are within 5 kb of a gene
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805locus and are therefore likely to represent active en-
hancers of a gene. Extrapolating to the whole genome,
this indicates that Mef2 regulates as many as 1000 genes
during the course of muscle development.
The current view of Mef2 in the literature is of a tran-
scription factor required late in development for muscle
differentiation. However, given the diversity of Mef2 tar-
get genes, its ability to regulate genes during all stages
of muscle development, and the huge number of en-
hancer regions bound by Mef2, our view of the function
of the transcription factor needs to be adjusted. Mef2 is
likely to bind to enhancer regions of most, if not all, mus-
cle genes, not just structural muscle proteins, and may
thereby act as a ‘‘general’’ muscle transcription factor.
The presence of feed-forward loops regulated by Mef2
(see Supplemental Results) as well as of low-penetrance
phenotypes in Mef2 mutants suggests that one of the
functions of this transcription factor is to provide robust-
ness within the myogenic program.
Concluding Remarks
We present a systematic analysis of Mef2 activity during
a time course of Drosophila embryogenesis by using
two complementary genomic approaches. This unique
combination provides insights into the function of this
transcription factor at a number of levels: the identifica-
tion of a large number of Mef2 bound enhancers pro-
vides a first step to decipher the regulatory network gov-
erning myogenesis. The dynamic aspect of Mef2 DNA
binding reveals mechanistic insight into the regulation
of Mef2’s activity. The identification of Mef2’s direct tar-
get genes allows a molecular understanding of the com-
plex phenotypes observed in Mef2 mutants. Finally, the
integration of these data provides a new view of this
transcription factor as a broad modulator of muscle
gene expression.
This combination of positional and temporal informa-
tion, derived from genomic approaches, can be applied
to any transcription factor. Such studies on other regu-
lators will allow the identification of overlapping and dis-
tinct enhancer regions, which are used dynamically dur-
ing discrete stages of development. This combinatorial
network of transcription factor activities is essential to
elucidate the regulatory code required for complex de-
velopmental programs.
Experimental Procedures
Chromatin Immunoprecipitation and DNA Amplification
A detailed description of the chromatin immunoprecipitation
method can be found in the Supplemental Data. In brief, for each
time point studied, four independent staged wild-type embryo pop-
ulations were collected. The chromatin samples were prepared from
tightly staged 2 hr embryo collections (Table S1). Antisera were
raised against amino acids 1–294 of dMef2 isoform IV (Gunthorpe
et al., 1999), which was purified from E. coli with poly-His tag affinity
purification. Sera from two different rabbits were used to exclude
serum-dependent biases. Two ChIP replicates were performed
with a-Mef2 antibody-A, and two were performed with a-Mef2 anti-
body-B (Figure 1B). Mock immunoprecipitations were performed by
using preimmunesera on each chromatin sample, leading to a total
of eight reactions (4 mock, 4 a-dMef2) per time point. Dye swaps
were included to account for possible dye biases. The DNA labeling
and hybridizations were performed as described in the Supplemen-
tal Data.Expression Profiling of Mef2 Loss-of-Function Mutants
The assayed Mef222.21 (Bour et al., 1995) line was generated by out-
crossing the original line twice to wild-type flies (Canton S). One hr
embryo collections of Mef2 mutants and Canton S were collected
and aged together, as described in Furlong et al., (2001a; 2001b). Af-
ter selecting the homozygous mutants with an automated embryo
sorter, any unfertilized embryos were subsequently removed by
hand. The staging of all collections was verified by formaldehyde
fixation of a small sample to ensure that wild-type and mutant em-
bryos were tightly stage matched (Table S6). For each developmen-
tal time point assayed, four independent embryo collections, sorts,
and hybridizations were performed. A detailed protocol of the RNA
amplification, labeling, and hybridization is available in the Supple-
mental Data.
Analysis of Array Data
The raw data from both tiling and cDNA arrays were normalized
by using print-tip and LOWESS normalization. To identify ChIP-en-
riched fragments, the experimental samples were hybridized against
genomic DNA. The four mock/genomic DNA and four ChIP/genomic
DNA ratios were compared in a two-class SAM analysis (Tusher et al.,
2001). The false-discovery rate was estimated by calculating q
values. Only fragments with q < 0.01 and a fold enrichment > 1.6
(log2 > 0.7) were considered to be significantly enriched.
To identify differentially expressed genes inMef2mutant embryos,
the experimental Mef2 mutant samples were hybridized directly
against the stage-matched wild-type samples. A one-class SAM
analysis was performed on four independent biological repeats for
each time point. Genes with a q < 0.05 and a fold enrichment of
log2 > 0.7 or <20.7 at two consecutive time points were considered
to be differentially regulated.
The assignment of ChIP-enriched fragments to target genes is de-
scribed in detail in the Supplemental Data. Mef2 binding and mutant
expression data can be visualized by using a searchable web site
(http://furlonglab.embl.de/data/).
Generation of Transgenic Reporter Strains
Fragments within the following coordinates were cloned into the
pH-stinger vector (Barolo et al., 2000) for germline transforma-
tion: chr3R:26000269–26001748 (Mlc2), chr3R:6616700–6618790
(CG14687), chr2L:1162075–1163021 (CG5080), chr2R:14886267–
14886639 (CG9416), chr3R:19167526–19169991 (pnt) (coordinates
based on genome release 4.2). For all constructs, except
CG5080’s regulatory region, at least two independent transgenic
lines were obtained and assayed.
To ectopically express Mef2 under the control of the UAS/Gal4
system, Mef2 cDNA isoform IV (Gunthorpe et al., 1999) was fused
to 3HA-epitope tags at the 30 end and cloned into the pUAST vector
(Brand and Perrimon, 1993). The presence of the epitope tag did not
lead to any discernable difference from the described UAS-DMef2
lines. The UAS-lmd line has been described previously as UAS-gfl
(Furlong et al., 2001a).
Histological Techniques
In situ hybridizations were done as described previously (Furlong
et al., 2001a). The following ESTs were used to generate DIG-labeled
probes: GH22991 (delilah), LD34147 (CG5080), RE70039 (Him),
RE28322 (CG9416), and RE42467 (CG30080). The probe for
Mlc2 was generated from the largest exon (chr3R:25,998,722-
25,999,116). GFP expression in transgenic animals was detected
by immunohistochemistry with rabbit a-GFP antibody (Torrey Pines
Biolabs) at a concentration of 1:500. Biotinylated secondary anti-
bodies were used in combination with the Vector Elite ABC kit (Vec-
tor Laboratories).
Estimating Overrepresentation of Binding Sites in Pulled-Down
Fragments
A detailed description is available in Supplemental Data. In brief,
known binding sites for Mef2 and Twist were used to generate posi-
tion-specific scoring matrices by using MEME. The MAST software
was used to predict binding sites in the Mef2 bound fragments as
well as in all fragments covered on the array (background) (Bailey
and Gribskov, 1998). The significant enrichment of predicted sites
in the enriched fragments was estimated by using Fisher’s exact
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806test, and the p values were adjusted for multiple testing by using the
Benjamini and Hocherg method.
Supplemental Data
Supplemental Data include all Mef2 bound regions, gene assign-
ments, expression profiling data, graphical representations of
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